Revumenib
SNDX-5613-0710
Phase 3 small_molecule active
Quick answer
Revumenib for Acute Myeloid Leukemias is a Phase 3 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Acute Myeloid Leukemias
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active